Every year the Everis Foundation organizes the Everis Awards event, a prestigious recognition of innovation, research and entrepreneurship, where companies in the technological sector from all over the world present their candidatures.

Last January, the foundation opened the registration period for those projects that aspire to win the 17th Everis Awards. The projects were classified into three main categories: new business models in the digital economy, industrial technologies and biotechnology and health. MJN, with its auricular device to evaluate the risk of epileptic seizure, entered the competition in this last modality.

Since 2016, MJN has taken part in every edition of the Everis awards, defending our device among a total of almost one thousand projects from twenty countries. But it has not been until now that we have managed to reach the final.

In this last edition, out of the 61 projects selected in the semi-final it was announced that MJN had qualified as one of the 6 finalists to compete for the Everis 2018 Award. Thus we were able to defend our work before a panel of experts composed of investors, business executives and representatives of the Everis group. We were recognized with a secondary award prize of 10,000 Euros and consultancy services. This is undoubtedly very good news for our project, as we now have more resources to continue developing and improving MJN-SERAS, making it known to the world and making it a reality in a short time.

MJN-SERAS

Find out your risk of having an epilepsy crisis at any time and place.

Leave a Reply

Abrir chat
1
Contacta con nosotros al momento
Chat con Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.